GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2007

Javelin Pharmaceuticals Signs Supply Pact with Baxter Healthcare

  • Baxter Healthcare inked a commercial supply agreement with Javelin Pharmaceuticals to provide additional manufacturing capacity for Javelin's injectable diclofenac, Dyloject™.

    Dylojectinjectable diclofenac sodium is under review for marketing approval in the U.K. for the treatment of acute moderate-to-severe pain. In the U.S., Dyloject is in Phase III trials for the same indication.

    Baxter will serve as a secondary manufacturer of Dyloject pending regulatory approval. The deal, which supplements an existing collaboration, has a three-year, renewable term and sets forth minimum purchase and production requirements.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?